[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].

Most targeted anticancer therapies induce dermatological toxicities that are often predominant. In particular, pigmentary changes are frequent and relatively characteristic, and they present most often as depigmentation. In this review, we describe the main pigmentary disorders observed with these new therapies, which affect the skin, hair, nails and mucous membranes. Hyperpigmentation secondary to MEK or EGFR inhibitors will be described, as well as forms of hypopigmentation specific to several tyrosine kinase inhibitors (imatinib, sunitinib and pazopanib), blue dots induced by vandetanib, and eruptive naevus triggered by RAF inhibitors. Vitiligoid reactions to CTLA4 and PD1/PD-L1 blocking agents will also be described.